Diabetes Day for Academic Primary Care Clinicians, December 2, 2017

Atlanta, GA US
December 2, 2017

There are approximately 130 university programs and over 300 community training programs in the U.S. Academic primary care physicians are in charge of educating students, residents and fellows, but their knowledge about diabetes care is not better than non-academic physicians. This educational shortfall is somewhat due to institutional limitations on attending industry supported meetings.  In addition, at Emory University, as in most academic centers, the PCPs do not attend weekly endocrine-diabetes division lectures, and there is only one diabetes grand round lecture per year.  Simply stated, the academic primary care physician needs more education on type 2 diabetes treatment, including updates on new insulins and combination agents, monitoring, and technology advances.

Target Audience

This activity has been designated to meet the educational needs of primary care physicians, nurse practitioners, physician assistants, residents, fellows in training and other healthcare professionals directly involved in the management of patients with type 2 diabetes and those who teach medical students, residents and fellows.

Learning Objectives

1.  How to use A1c level to decide options for initial therapy

2.  Understand when insulin should be part of initial or transition of therapy

3.  Present the biological and environmental factors contributing to the obesity epidemic.

4.  Discuss lifestyle modification therapy for patients with obesity, prediabetes, and diabetes.

5. Outline the model for care of the patient with overweight or obesity, based on the AACE algorithms.

6. Explain the implications of lifestyle modification on the prevention of prediabetes and diabetes.

7. Present recent data from randomized controlled studies on the safety and efficacy of oral combination therapy in the management of patients with type 2 diabetes

8. Discuss current evidence on how best to intensified therapy with the use of oral antidiabetic agents

9. Discuss clinical scenarios on how to select oral agents after metformin therapy

10. Discuss the pathophysiology of beta-cell failure in patients with type 2 diabetes that lead to insulinopenia and insulin need

11. Discuss the current and future paradigm on insulin initiation and intensification for the management of Type 2 diabetes

12. Discuss new insulin agents for the management of diabets

13. Why all patients with T2DM should be treated with statin therapy

14. Describe glucose lowering therapies that have been shown to benefit risk of CV events

15. Be knowledgeable of the indications of glucose monitoring systems including Flash Glucose monitoring and Continuous

16.  Glucose Monitoring

17. Be knowledgeable of the indications for Insulin Pump Therapy and Sensor Augmented Insulin Pump Therapy including

18. Hybrid Closed Loop systems.

19. Discuss regimens to break treatment inertia in order to improve glycemic control in patients with diabetes

Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 4.50 AMA
  • 4.50 Attendance
Course opens: 
12/02/2017
Course expires: 
12/02/2018
Event starts: 
12/02/2017 - 7:00am
Event ends: 
12/02/2017 - 1:00pm
Cost:
$0.00
7:00 - 8:00 AMBreakfast and Exhibits 
8:00 - 8:10 AMWelcome and Introduction 
Guillermo Umpierrez, MD, FACP, FACE
8:10 - 8:30 AMAACE Comprehensive Diabetes Management Algorithm 2017 
Kittie Wyne, MD, PhD, FNLA, FACE
Objectives:
  1. How to use A1c level to decide options for initial therapy
  2. Understand when insulin should be part of initial or transition of therapy
8:30 - 9:00 AMLifestyle Therapy 
Scott Isaacs, MD, FACP, FACE
Objectives:
  1. Present the biological and environmental factors contributing to the obesity epidemic.
  2. Discuss lifestyle modification therapy for patients with obesity, prediabetes, and diabetes.
  3. Outline the model for care of the patient with overweight or obesity, based on the AACE algorithms.
  4. Explain the implications of lifestyle modification on the prevention of prediabetes and diabetes.
9:00 - 10:00 AMUpdate on Oral Agents and Noninsulin Injectables for T2D 
Patrick Bowen, MD
Objectives:
  1. Present recent data from randomized controlled studies on the safety and efficacy of oral combination therapy in the management of patients with type 2 diabetes
  2. Discuss current evidence on how best to intensified therapy with the use of oral antidiabetic agents
  3. Discuss clinical scenarios on how to select oral agents after metformin therapy
10:00 - 10:30 AMBreak and Exhibits 
10:30 - 11:05 AMUpdate on Insulin Based Agents for T2D 
Guillermo Umpierrez, MD, FACP, FACE
Objectives:
  1. Discuss the pathophysiology of beta-cell failure in patients with type 2 diabetes that lead to insulinopenia and insulin need
  2. Discuss the current and future paradigm on insulin initiation and intensification for the management of Type 2 diabetes
  3. Discuss new insulin agents for the management of diabets
11:05 - 11:45 AMCardiovascular Risk Management in Patients with T2D 
Kittie Wyne, MD, PhD, FNLA, FACE
Objectives:
  1. Why all patients with T2DM should be treated with statin therapy
  2. Describe glucose lowering therapies that have been shown to benefit risk of CV events
11:45 AM - 12:15 PMAdvances in Diabetes Care Technologies 
Bruce Bode, MD, FACE
Objectives:
  1. Be knowledgeable of the indications of glucose monitoring systems including Flash Glucose monitoring and Continuous Glucose Monitoring
  2. Be knowledgeable of the indications for Insulin Pump Therapy and Sensor Augmented Insulin Pump Therapy including Hybrid Closed Loop systems.
12:15 - 1:00 PMApplication of the Diabetes Algorithm to a Patient 
Moderator: Guillermo Umpierrez, MD, FACP, FACE
Panel: Brude Bode, MD; Priya Vellanki, MD;
Fred Turton, MD; Francisco Pasquel, MD
  1. Provide clinical cases to illustrate the need for treatment intensification in patients with type 2 diabetes
  2. Discuss regimens to break treatment inertia in order to improve glycemic control in patients with diabetes
1:00 PMAdjourn 
Emory Conference Center
1615 Clifton Road
Atlanta, GA 30329
United States

*Guillermo Umpierrez MD, FACP, FACE, CDE

Program Chair

 Professor of Medicine

Emory University School of Medicine

Director Endocrinology Section

Grady Health System

Atlanta, GA

*Bruce W. Bode, MD, FACE

Atlanta Diabetes Associates

Associate Professor of Medicine

Emory University School of Medicine

Atlanta, GA

Patrick Bowen, MD

Assistant Professor, Distinguished Physician

Division of Endocrinology, Metabolism and Lipids

Emory University School of Medicine

Service Chief, Endocrinology

Emory Healthcare / The Emory Clinic

Atlanta, GA

*Scott D Isaacs, MD, FACP, FACE

Adjunct Instructor of Medicine

Emory University School of Medicine

Medical Director

Atlanta Endocrine Associates

Atlanta, GA

Francisco J Pasquel, MD, MPH, FACE

Assistant Professor of Medicine

Emory University School of Medicine

Atlanta, GA

Frederick E Turton, MD, MBA, MACP

Assistant Professor of Medicine

Emory University School of Medicine

Medical Director Primary Care

Emory Healthcare

Atlanta, GA

Priyathama Vellanki, MD

Assistant Professor of Medicine

Division of Endocrinology, Metabolism and Lipids

Grady Memorial Hospital

Emory University School of Medicine

Atlanta, GA

Kathleen Wyne, MD, PhD, FACE, FNLA

Director, Adult Type 1 Diabetes Program

Associate Professor of Clinical Medicine

Division of Diabetes, Endocrinology and Metabolism

The Ohio State University Wexner Medical Center

Columbus, OH

*Indicates individual is also a member of the program committee

Available Credit

  • 4.50 AMA
  • 4.50 Attendance

Accreditation Period

Course opens: 
12/02/2017
Course expires: 
12/02/2018

Price

Cost:
$0.00
Please login or register to take this course.